144 related articles for article (PubMed ID: 2181382)
1. Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer.
Lemoine NR; Staddon S; Dickson C; Barnes DM; Gullick WJ
Oncogene; 1990 Feb; 5(2):237-9. PubMed ID: 2181382
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of potential oncogene alterations in the ENU1564 rat mammary tumor model.
Hal DG; Stoica G
Anticancer Res; 1994; 14(2A):481-7. PubMed ID: 7912494
[TBL] [Abstract][Full Text] [Related]
3. Oncogene patterns in breast and ovarian carcinomas.
Csókay B; Papp J; Besznyák I; Bösze P; Sárosi Z; Tóth J; Zalay Z; Oláh E
Eur J Surg Oncol; 1993 Dec; 19(6):593-9. PubMed ID: 7903645
[TBL] [Abstract][Full Text] [Related]
4. The c-erb B-2 proto-oncogene in human pancreatic cancer.
Hall PA; Hughes CM; Staddon SL; Richman PI; Gullick WJ; Lemoine NR
J Pathol; 1990 Jul; 161(3):195-200. PubMed ID: 2202801
[TBL] [Abstract][Full Text] [Related]
5. erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.
Ethier SP; Kokeny KE; Ridings JW; Dilts CA
Cancer Res; 1996 Feb; 56(4):899-907. PubMed ID: 8631031
[TBL] [Abstract][Full Text] [Related]
6. neu proto-oncogene mutation is specific for the neurofibromas in a N-nitroso-N-ethylurea-induced hamster neurofibromatosis model but not for hamster melanomas and human Schwann cell tumors.
Nakamura T; Ushijima T; Ishizaka Y; Nagao M; Nemoto T; Hara M; Ishikawa T
Cancer Res; 1994 Feb; 54(4):976-80. PubMed ID: 7906199
[TBL] [Abstract][Full Text] [Related]
7. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.
Garcia I; Dietrich PY; Aapro M; Vauthier G; Vadas L; Engel E
Cancer Res; 1989 Dec; 49(23):6675-9. PubMed ID: 2573420
[TBL] [Abstract][Full Text] [Related]
8. Assessment of c-erbB-2 amplification by immunohistochemistry in paraffin-embedded breast cancer.
Kerns BJ; Jordan PA; Huper G; Marks JR; Iglehart JD; Layfied LJ
Mod Pathol; 1993 Nov; 6(6):673-8. PubMed ID: 7905629
[TBL] [Abstract][Full Text] [Related]
9. Amplification of epidermal growth factor receptor gene but no evidence of ras mutations in primary human esophageal cancers.
Hollstein MC; Smits AM; Galiana C; Yamasaki H; Bos JL; Mandard A; Partensky C; Montesano R
Cancer Res; 1988 Sep; 48(18):5119-23. PubMed ID: 3044581
[TBL] [Abstract][Full Text] [Related]
10. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation.
Weiner DB; Liu J; Cohen JA; Williams WV; Greene MI
Nature; 1989 May; 339(6221):230-1. PubMed ID: 2654648
[TBL] [Abstract][Full Text] [Related]
11. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations.
Gaffey MJ; Frierson HF; Williams ME
Mod Pathol; 1993 Nov; 6(6):654-9. PubMed ID: 7905628
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the int-1, int-2, c-myc, and neu oncogenes in human breast carcinomas.
Meyers SL; O'Brien MT; Smith T; Dudley JP
Cancer Res; 1990 Sep; 50(18):5911-8. PubMed ID: 1975511
[TBL] [Abstract][Full Text] [Related]
13. Amplification and rearrangement of c-erb B proto-oncogenes in cancer of human female genital tract.
Zhang X; Silva E; Gershenson D; Hung MC
Oncogene; 1989 Aug; 4(8):985-9. PubMed ID: 2569708
[TBL] [Abstract][Full Text] [Related]
14. Neu and its ligands: from an oncogene to neural factors.
Peles E; Yarden Y
Bioessays; 1993 Dec; 15(12):815-24. PubMed ID: 7908191
[TBL] [Abstract][Full Text] [Related]
15. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.
Furitsu T; Tsujimura T; Tono T; Ikeda H; Kitayama H; Koshimizu U; Sugahara H; Butterfield JH; Ashman LK; Kanayama Y
J Clin Invest; 1993 Oct; 92(4):1736-44. PubMed ID: 7691885
[TBL] [Abstract][Full Text] [Related]
16. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
[TBL] [Abstract][Full Text] [Related]
17. Characterization of an angiosarcoma-inducing mutation in the erbB oncogene.
Robinson HL; Tracy SE; Nair N; Taglienti-Sian C; Gamett DC
Oncogene; 1992 Oct; 7(10):2025-30. PubMed ID: 1408143
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis.
Guérin M; Barrois M; Terrier MJ; Spielmann M; Riou G
Oncogene Res; 1988; 3(1):21-31. PubMed ID: 2905033
[TBL] [Abstract][Full Text] [Related]
19. Molecular genetics of malignant insulinoma.
Pavelic K; Hrascan R; Kapitanovic S; Vranes Z; Cabrijan T; Spaventi S; Korsic M; Krizanac S; Li YQ; Stambrook P; Gluckman JL; Pavelic ZP
Anticancer Res; 1996; 16(4A):1707-17. PubMed ID: 8712689
[TBL] [Abstract][Full Text] [Related]
20. A single point mutation responsible for c-mos polymorphism in cancer patients.
Lidereau R; Cole ST; Larsen CJ; Mathieu-Mahul D
Oncogene; 1987 May; 1(2):235-7. PubMed ID: 2894001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]